- Home
- RLGT vs TVRD Comparison
RLGT vs TVRD Comparison
Compare RLGT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLGT
- TVRD
- Stock Information
- Founded
- RLGT 2001
- TVRD 2017
- Country
- RLGT United States
- TVRD United States
- Employees
- RLGT N/A
- TVRD N/A
- Industry
- RLGT Oil Refining/Marketing
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- RLGT Consumer Discretionary
- TVRD Health Care
- Exchange
- RLGT Nasdaq
- TVRD Nasdaq
- Market Cap
- RLGT 280.5M
- TVRD 246.5M
- IPO Year
- RLGT N/A
- TVRD N/A
- Fundamental
- Price
- RLGT $6.16
- TVRD $33.83
- Analyst Decision
- RLGT Strong Buy
- TVRD Strong Buy
- Analyst Count
- RLGT 1
- TVRD 5
- Target Price
- RLGT $8.00
- TVRD $59.20
- AVG Volume (30 Days)
- RLGT 146.4K
- TVRD 22.8K
- Earning Date
- RLGT 09-15-2025
- TVRD 08-14-2025
- Dividend Yield
- RLGT N/A
- TVRD N/A
- EPS Growth
- RLGT 118.75
- TVRD N/A
- EPS
- RLGT 0.35
- TVRD N/A
- Revenue
- RLGT $902,696,000.00
- TVRD N/A
- Revenue This Year
- RLGT $7.61
- TVRD N/A
- Revenue Next Year
- RLGT N/A
- TVRD N/A
- P/E Ratio
- RLGT $17.86
- TVRD N/A
- Revenue Growth
- RLGT 12.49
- TVRD N/A
- 52 Week Low
- RLGT $5.44
- TVRD $8.13
- 52 Week High
- RLGT $7.94
- TVRD $36.71
- Technical
- Relative Strength Index (RSI)
- RLGT 51.12
- TVRD 54.26
- Support Level
- RLGT N/A
- TVRD N/A
- Resistance Level
- RLGT $6.48
- TVRD $36.71
- Average True Range (ATR)
- RLGT 0.15
- TVRD 1.93
- MACD
- RLGT -0.26
- TVRD -0.88
- Stochastic Oscillator
- RLGT 92.70
- TVRD 92.15
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.